Free Trial

BioSyent (CVE:RX) Stock Price Passes Below Fifty Day Moving Average - Here's Why

BioSyent logo with Medical background

BioSyent Inc. (CVE:RX - Get Free Report)'s share price passed below its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of C$11.66 and traded as low as C$11.41. BioSyent shares last traded at C$11.41, with a volume of 6,100 shares.

BioSyent Trading Up 0.4%

The company has a market cap of C$130.96 million, a PE ratio of 18.58 and a beta of 0.93. The business has a 50 day simple moving average of C$11.67 and a two-hundred day simple moving average of C$11.17. The company has a current ratio of 3.92, a quick ratio of 6.91 and a debt-to-equity ratio of 2.90.

About BioSyent

(Get Free Report)

BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia.

Featured Stories

Should You Invest $1,000 in BioSyent Right Now?

Before you consider BioSyent, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioSyent wasn't on the list.

While BioSyent currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters
This Strategy Beat the S&P—And Most Investors Ignore It
NVDA Greenlight: China Sales Spark 50% Rally Potential

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines